Your fact-checks will appear here
Progressive, neurodegenerative disease characterized by memory loss
Laboratory and animal studies consistently report that honey and its polyphenolic constituents have antioxidant, anti-inflammatory, and enzyme-modulating effects that can protect neurons, improve syna...
Neurocept’s investigational compound NE3107 has been evaluated in a Phase 2, open‑label study that reported , suggesting potential efficacy and a safety signal that supports further testing . Independ...
Available reporting shows no credible evidence that Dr. Sanjay Gupta is part of Neurocept’s leadership or an investor; multiple sources document his likeness being used in deepfake ads to sell bogus s...
Dr. Sanjay Gupta has publicly presented a mix of cautious optimism about new drugs like Leqembi and a strong emphasis on lifestyle and “cognitive reserve” approaches to slow or reduce dementia risk. H...
Lecanemab and donanemab are two recently approved anti‑amyloid monoclonal antibodies tested in large, randomized trials in early Alzheimer’s disease that both produced substantial amyloid PET clearanc...
Dr. Paul Alan Cox is identified in multiple outlets as the leader of Brain Chemistry Labs (also called the Institute for Ethnomedicine or Brain Chemistry Labs / The Institute for EthnoMedicine) — serv...
Neurocept’s claimed benefits for Alzheimer's disease are and cannot be robustly compared with established Alzheimer’s treatments. Independent clinical-trial evidence and regulatory approval for Neuroc...
A randomized phase‑2 trial of an intensive, multimodal lifestyle intervention reported measurable improvements in cognition and function after 20 weeks among people with mild cognitive impairment (MCI...
Clinical trials and systematic reviews suggest Bacopa monnieri shows modest, reproducible signals for improving aspects of cognition—most consistently speed of attention and some measures of memory re...
Elon Musk has repeatedly positioned Neuralink — the brain-computer interface company he co‑founded — as a technology that could one day address conditions such as dementia, and he has publicly touted ...
Randomized trials and several systematic reviews and meta-analyses identify non‑pharmacological approaches—structured cognitive interventions (including computerized cognitive training) and exercise p...
Available reporting and indexed medical literature in the provided search results do not identify any peer‑reviewed clinical trials of a product called “Neurocept,” nor do they list trial authors for ...
Public reporting shows mainly marketing pieces, user testimonials, and consumer complaints about Neurocept; independent, product-level clinical trials or peer‑reviewed efficacy data for the supplement...
Available reporting in the provided results does not show any peer‑reviewed or regulator‑facing phase trial readouts for a prescription drug named “Neurocept”; instead, the material is marketing, revi...
Recent multidomain randomized trials and large observational reviews show evidence that combining diet and exercise can slow cognitive decline; randomized trials like FINGER report cognitive benefits ...
Dr. Sanjay Gupta did not reference any clinical trial evidence supporting Neurocept’s efficacy in the materials and investigations reviewed; independent fact-checking shows his likeness was used in an...
Dementia describes a chronic, progressive decline in multiple cognitive domains — memory, language, attention, executive function and social cognition — that impairs daily functioning; clinical diagno...